Genetic and metabolic determinants of plasma PCSK9 levels. - Wikidata - awgldk - TriplyDB

Genetic and metabolic determinants of plasma PCSK9 levels.

Genetic and metabolic determinants of plasma PCSK9 levels.

http://www.wikidata.org/entity/Q34974626

about

The PCSK9 decade PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications PCSK9 and triglyceride-rich lipoprotein metabolism Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels.Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.PCSK9 and Atherosclerosis - Lipids and Beyond.PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies What lies ahead for the proprotein convertases?Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans.Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets.Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.Comparison of statistical tests for association between rare variants and binary traits.Population genetic analysis of the uncoupling proteins supports a role for UCP3 in human cold resistance.Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin.Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol.Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people Birth Cohort, Age, and Sex Strongly Modulate Effects of Lipid Risk Alleles Identified in Genome-Wide Association Studies.Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9.PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans.PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice.Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.

P2860

Q24615397-10895531-3E23-4BD8-B896-1D2FCDC0548C Q24633470-FDAB01AA-8014-4841-8499-65D42C0C611D Q26741078-C7F8F9C7-18DC-4D06-86AD-4DF9D02900A3 Q26796287-A76E739C-02ED-40E3-846A-CDCA6CC0AD98 Q27003094-FC5C5560-FA58-41A2-8BE0-A2ECFE66065C Q27009477-5817ABFF-0477-443A-91DC-5EC032EA5000 Q27665195-DA164AEB-DBA1-4921-A513-96F2519A34D6 Q33577851-67B181B9-01FD-4B87-9A1C-2F443D8ACC8D Q33599961-82E4810E-81A0-41D2-B552-BD479E062292 Q33675963-F7C1F10C-CCD9-4CD3-BCB7-B19E04C29463 Q33904455-D0B6BB1E-9688-4087-8A48-C933A5332B7F Q33970677-92AEE687-587F-427C-ABE0-93B7BA6BDFB3 Q34047773-F87A6DC8-C256-40F9-9532-39F7222F944D Q34053143-630AE736-79B0-4EF0-BE02-E476D06F4A42 Q34122388-A382387B-3116-4A02-AC5C-36494B64420A Q34169463-BFC7E6F6-1813-4256-9EED-524FE21CFF92 Q34188114-BBBE807B-E51A-475D-B2A7-696B4B865085 Q34321484-06A67B88-E070-4246-87B8-55169AE1A955 Q34375398-03C1606B-D65C-4751-9C0B-06739694555F Q34388775-A1359287-A481-4F06-8773-C7C725B93C27 Q34407779-82DADF46-CB54-4E73-9A10-0C56D9A46D6B Q34430377-F3200829-A664-4A88-ABD6-2BE4F2DE4AB4 Q34433146-B3077605-F1FD-4AE7-A483-3AD2E9313D73 Q34458693-59997A55-7DDA-4345-AC10-7490ABA4FC96 Q34536594-3929F60D-7C0B-4D2C-A1AE-4AB294A858B5 Q34662589-D7D1E7BC-D156-4790-BB82-5454155D26A8 Q34812315-8D2A0BF1-64A7-46A3-BBA0-4A8485E19D7C Q35014317-B4737A0D-28AB-4D33-9498-C9C4E751FDDD Q35436046-017848D8-7D49-4B40-9391-07E87900BC34 Q35752147-35AEB8FE-A1A5-42FB-B272-52134353368B Q35794774-9F230C3A-01BB-47A3-978E-03400BAD87C7 Q35901123-03C7CDFE-95EB-4710-AEF0-CBE6EB961693 Q35911079-A97F0323-D659-4109-8526-ED885F074283 Q35999550-8D4BCF07-78F3-4A90-9EF6-A69072C7701F Q36035643-2F42A2B9-B694-4970-8464-22DCCB170089 Q36196859-B0291D85-F06F-4518-AAAB-DEB31B110C3A Q36197840-538F3425-7858-4626-B25D-BC06E4F38A7C Q36529674-52AFE7AF-D02C-4104-B0AE-01B67460B7AC Q36554065-046AE731-DC4D-4A87-9E81-7409EE407C31 Q36574008-A3B44389-5DB2-4787-9B88-F6C8FD9F784B

P2860

Genetic and metabolic determinants of plasma PCSK9 levels.

http://www.wikidata.org/entity/Q34974626

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Genetic and metabolic determinants of plasma PCSK9 levels.

@ast

Genetic and metabolic determinants of plasma PCSK9 levels.

@en

Genetic and metabolic determinants of plasma PCSK9 levels.

@nl

type

label

Genetic and metabolic determinants of plasma PCSK9 levels.

@ast

Genetic and metabolic determinants of plasma PCSK9 levels.

@en

Genetic and metabolic determinants of plasma PCSK9 levels.

@nl

prefLabel

Genetic and metabolic determinants of plasma PCSK9 levels.

@ast

Genetic and metabolic determinants of plasma PCSK9 levels.

@en

Genetic and metabolic determinants of plasma PCSK9 levels.

@nl

P1433

Q34974626-8C3A481B-D84A-47DC-AA4D-3FB994ADFBBC

P1476

Q34974626-0F68A0A1-1F4D-415D-A986-D44A0F3D84DC

P2093

Q34974626-22B97501-5EAD-493C-941B-4EFA100C595E

Q34974626-52C5410E-EE32-4216-8FEE-B1A5F5532694

Q34974626-8A571283-BF49-4005-B419-77C66C99A173

Q34974626-C9BD760A-CA41-45A2-BF66-C4714A4C9F6B

Q34974626-F93583EB-E7CE-41B8-8187-84D570BC82BD

P2860

Q34974626-02B529B6-B7F7-4B34-8172-2BF9291826A2

Q34974626-0FB016C2-D620-4A60-ADCB-3CD2BEFB4BCB

Q34974626-113C8A96-B9E0-42FC-892F-A7BDBDF0B9E8

Q34974626-1168E24D-803C-4806-8215-699FA61DBD66

Q34974626-1291E09E-0FD4-4A1E-A6CD-DBE903DE2553

Q34974626-1885F569-AAFA-44D7-9021-44E0E4C4C2C5

Q34974626-18E1AB82-952E-4489-A2B4-6C4085E63594

Q34974626-2B094DAA-A8F9-404C-8A4C-C90EA155F1F7

Q34974626-3F0DEC67-90A1-4F88-AB4A-194BA79B3B3B

Q34974626-45154BB2-43D3-4A79-9B3E-5A1734D12229

P304

Q34974626-1E323BA3-3081-4488-A0F1-D7C3BF225394

P31

Q34974626-CA06B5CB-2DD0-4C42-B62B-C42D823183C1

P356

Q34974626-DBB6C639-2D2B-4C9C-9765-F998E68D8D91

P407

Q34974626-1C2110F3-2537-4B16-935F-8EA1FC50F419

P433

Q34974626-39BD89EB-F1EB-4E40-998B-E0850BF26140

P478

Q34974626-EA01A013-C374-4B17-A8DC-06DABA78343E

P577

Q34974626-9E06FC7B-7F22-42DE-ACC0-580E36F0CCBA

P5875

Q34974626-F752F1C1-C331-4293-A529-9C832FF1D580

P698

Q34974626-592C4079-8A61-4F6D-BE28-D2108E386D8A

P932

Q34974626-09EB1FF7-3DC6-4695-BCEA-AF3F00BC4F21

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Genetic and metabolic determinants of plasma PCSK9 levels.

@en

P2093

Helen H Hobbs

http://www.w3.org/2001/XMLSchema#string

Jay D Horton

http://www.w3.org/2001/XMLSchema#string

Jonathan C Cohen

http://www.w3.org/2001/XMLSchema#string

Susan G Lakoski

http://www.w3.org/2001/XMLSchema#string

Thomas A Lagace

http://www.w3.org/2001/XMLSchema#string

P2860

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes

Molecular biology of PCSK9: its role in LDL metabolism

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

A receptor-mediated pathway for cholesterol homeostasis

P304

2537-2543

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2009-0141

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24262671

http://www.w3.org/2001/XMLSchema#string

P698

19351729

http://www.w3.org/2001/XMLSchema#string

P932

2708952

http://www.w3.org/2001/XMLSchema#string